PF-Atlas › Clinical Trials › NCT00659529

Safety and Efficacy of Sildenafil in Cystic Fibrosis Lung Disease

sildenafil · Phase 1

Registry ID
NCT00659529
Phase
Phase 1
Status
Completed
Drug / intervention
sildenafil
Sponsor
National Jewish Health
Start
2008-08
Enrollment
36
Locations
1

About this trial

The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.

View NCT00659529 on ClinicalTrials.gov →

Explore related

All sildenafil trialsAll IPF trials

Related trials

sildenafil — NCT00359736Sildenafil — NCT00352482Sildenafil — NCT01194232Sildenafil — NCT02057458Sildenafil — NCT00981747sildenafil — NCT02626182
Medical disclaimer. This page summarizes public trial data for NCT00659529 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.